Human paraoxonase 1 (PON1) is a calcium-dependent high-density lipoprotein associated ester hydrolase that has attracted considerable attention as a candidate factor for coronary heart disease (CHD) based on its function as a key factor in lipoprotein catabolism pathways. This meta-analysis aimed to clarify the inconsistency of published studies and to establish a comprehensive picture of the relationship between PON1 activity and CHD susceptibility. A systematic search was performed from PubMed, Web of Science, EMBASE, and CNKI databases. Ratio of means (RoM) between case and control and 95% confidence intervals (CIs) were calculated using a random-effects model. The source of heterogeneity was explored by subgroup analysis and meta-regression. We identified 47 eligible studies including a total of 9853 CHD cases and 11,408 controls. The pooled analysis showed that CHD patients had a 19% lower PON1 activity than did the controls (RoM=0.81; 95% CI: 0.74–0.89, p<10−5). In the subgroup analyses by CHD end points, a similar effect size was observed with coronary stenosis and myocardial infarction subgroups, with corresponding RoM of 0.81 (95% CI: 0.73–0.89, p<10−4) and 0.83 (95% CI: 0.74–0.93, p=0.001), respectively. Decreased PON1 activity associated with CHD risk was observed in almost all subgroup analysis according to ethnicity, sample size, study design, mean age of cases, source, and type of control. Decreased PON1 activity may act as a risk factor for the development of CHD. Progressive decrease in serum PON1 activity may exist for an individual with severe disease. However, larger studies using a prospective approach are needed to confirm our results.
Get full access to this article
View all access options for this article.
References
1.
AydinM., GokkusuC., OzkokE., TulubasF., UnlucerciY., PamukcuB., OzbekZ., UmmanB.2009. Association of genetic variants in Methylenetetrahydrofolate Reductase and Paraoxonase-1 genes with homocysteine, folate and vitamin B12 in coronary artery disease. Mol Cell Biochem, 325:199–208.
AzarsizE., KayikciogluM., PayzinS., Yildirim SözmenE.2003. PON1 activities and oxidative markers of LDL in patients with angiographically proven coronary artery disease. Int J Cardiol, 91:43–51.
4.
BaiL., MaA.Q., DiT.2002. Correlation of serum paraoxonase activity with coronary heart disease. Di Si Jun Yi Da Xue Xue Bao, 23:3.
5.
BhattacharyyaT., NichollsS.J., TopolE.J.et al.2008. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA, 299:1265–1276.
6.
BirjmohunR.S., VergeerM., StroesE.S.et al.2009. Both paraoxonase-1 genotype and activity do not predict the risk of future coronary artery disease; the EPIC-Norfolk Prospective Population Study. PLoS One, 4:e6809.
7.
Blatter GarinM.C., MorenX., JamesR.W.2006. Paraoxonase-1 and serum concentrations of HDL-cholesterol and apoA-I. J Lipid Res, 47:515–520.
8.
ChiD.S., LingW.H., MaJ., XiaM., HouM.J., WangQ., ZhuH.L., TangZ.H., YuX.P.2006. Study of the association between paraoxonase1 55 Met/Leu, paraoxonase2 148 Ala/Gly and manganese superoxide dismutase (MnSOD) 9 Ala/Val genetic polymorphisms and coronary heart disease. Zhonghua Liu Xing Bing Xue Za Zhi, 27:808–813.
9.
DerSimonianR., LairdN.1986. Meta-analysis in clinical trials. Control Clin Trials, 7:177–188.
EggerM., Davey SmithG., SchneiderM., MinderC.1997. Bias in meta-analysis detected by a simple, graphical test. BMJ, 315:629–634.
12.
FerréN., TousM., PaulA., ZamoraA., VendrellJ.J., BardajíA., CampsJ., RichartC., JovenJ.2002. Paraoxonase Gln-Arg(192) and Leu-Met(55) gene polymorphisms and enzyme activity in a population with a low rate of coronary heart disease. Clin Biochem, 35:197–203.
13.
FriedrichJ.O., AdhikariN.K., BeyeneJ.2008. The ratio of means method as an alternative to mean differences for analyzing continuous outcome variables in meta-analysis: a simulation study. BMC Med Res Methodol, 8:32.
14.
GamboaR., RegaladoJ.C., Huesca-GómezC., Posadas-RomeroC., Verdejo ParisJ., Vargas-AlarcónG., Pérez-MéndezO.2008. Low paraoxonase and arylesterase plasma activities in Mexican patients with coronary artery disease. Arch Cardiol Mex, 78:360–368.
15.
GöçmenA.Y., GümüşlüS., SemizE.2004. Association between paraoxonase-1 activity and lipid peroxidation indicator levels in people living in the Antalya region with angiographically documented coronary artery disease. Clin Cardiol, 27:426–430.
16.
GöçmenA.Y., SahinE., SemizE., GümuşlüS.2008. Is elevated serum ceruloplasmin level associated with increased risk of coronary artery disease?Can J Cardiol, 24:209–212.
17.
HasselwanderO., SavageD.A., McMasterD., LoughreyC.M., McNameeP.T., MiddletonD., NichollsD.P., MaxwellA.P., YoungI.S.1999. Paraoxonase polymorphisms are not associated with cardiovascular risk in renal transplant recipients. Kidney Int, 56:289–298.
18.
ItaharaT., SuehiroT., IkedaY.et al.2000. Serum paraoxonase and arylesterase activities in hemodialysis patients. J Atheroscler Thromb, 7:152–8.
19.
JamesR.W., LevievI., RuizJ., PassaP., FroguelP., GarinM.C.2000. Promoter polymorphism T(-107)C of the paraoxonase PON1 gene is a risk factor for coronary heart disease in type 2 diabetic patients. Diabetes, 49:1390–1393.
20.
KamanD., IlhanN., MetinK., AkbulutM., UstündağB.2009. A preliminary study of human paraoxonase and PON 1 L/M55-PON 1 Q/R 192 polymorphisms in Turkish patients with coronary artery disease. Cell Biochem Funct, 27:88–92.
21.
KarakayaA., IbişS., KuralT., KöseS.K., KarakayaA.E.1999. Serum paraoxonase activity and phenotype distribution in Turkish subjects with coronary heart disease and its relationship to serum lipids and lipoproteins. Chem Biol Interact, 118:193–200.
22.
KerkeniM., AddadF., ChauffertM., ChuniaudL., MiledA., TrivinF., MaaroufiK.2006. Hyperhomocysteinemia, paraoxonase activity and risk of coronary artery disease. Clin Biochem, 39:821–825.
23.
Kotur-StevuljevicJ., SpasicS., StefanovicA.et al.2006. Paraoxonase-1 (PON1) activity, but not PON1(Q192R) phenotype, is a predictor of coronary artery disease in a middle-aged Serbian population. Clin Chem Lab Med, 44:1206–1213.
24.
LacinskiM., SkorupskiW., CieslinskiA., SokolowskaJ., TrzeciakW.H., JakubowskiH.2004. Determinants of homocysteine-thiolactonase activity of the paraoxonase-1 (PON1) protein in humans. Cell Mol Biol (Noisy-le-grand), 50:885–893.
25.
LakshmyR., AhmadD., AbrahamR.A., SharmaM., VemparalaK., DasS., ReddyK.S., PrabhakaranD.2010. Paraoxonase gene Q192R & L55M polymorphisms in Indians with acute myocardial infarction & association with oxidized low density lipoprotein. Indian J Med Res, 131:522–529.
LiS.Y., LiJ.Y., WeiG., JiQ.D., WangP.X.2004. Study on the relationship between Paraoxonase-1 (PON-1) and Type 2 diabetes mellitus complicated by coronary artery disease. Tianjin Yi Yao, 32:273–276.
28.
LiuK.T., ZengG.F., LiuG.X., WangY., DingC.F.2000. The relation of serum paraoxonase activity and Gln-Arg 192 polymorphism with coronary heart disease. Lin Chuang Xin Xue Guan Bing Za Zhi, 16:148–150.
29.
LuC., GaoY., ZhouH., TianH.2008. The relationships between PON1 activity as well as oxLDL levels and coronary artery lesions in CHD patients with diabetes mellitus or impaired fasting glucose. Coron Artery Dis, 19:565–573.
30.
LuoY.P., OuB.Q., ZhangY., LianY., GuoY., ZhaoS.P.2008. Analysis of plasma paraoxonase 1 activity in patients with unstable angina. Zhongguo Yi Shi Za Zhi, 10:1121–1123.
31.
LuoY.P., ZhaoS.P., LiJ., NieS.2002. The change of serum paranoxonase-1 activity in patients with acute coronary syndrom. Zhongguo Dong Mai Ying Hua Za Zhi, 10:341–344.
MacknessB., DaviesG.K., TurkieW.et al.2001. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype?Arterioscler Thromb Vasc Biol, 21:1451–1457.
34.
MacknessB., DurringtonP., McElduffP., YarnellJ., AzamN., WattM., MacknessM.2003. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation, 107:2775–2779.
35.
MacknessB., HineD., McElduffP., MacknessM.2006. High C-reactive protein and low paraoxonase1 in diabetes as risk factors for coronary heart disease. Atherosclerosis, 186:396–401.
36.
MacknessM.I, AbbottC.A, ArrolS., DurringtonP.N.1993a. The role of high density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J, 294:829–835.
37.
MacknessM.I., ArrolS., AbbottC.A., DurringtonP.N.1993b. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis, 104:129–135.
38.
MacknessM.I., ArrolS., DurringtonP.N.1991. Paranoxonase prevents accumulation of lipoperoxides in low density lipoprotein. FEBS Lett, 286:152–154.
39.
MacknessM.I., DurringtonP.N.1995. High density lipoprotein, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis, 115:243–253.
40.
MartinelliN., GirelliD., OlivieriO.et al.2009. Novel serum paraoxonase activity assays are associated with coronary artery disease. Clin Chem Lab Med, 47:432–440.
41.
MohamedR.H., MohamedR.H., KaramR.A., Abd El-AzizT.A.2010. The relationship between paraoxonase1-192 polymorphism and activity with coronary artery disease. Clin Biochem, 43:553–558.
42.
NajafiM., GohariL.H., FiroozraiM.2009. Paraoxonase 1 gene promoter polymorphisms are associated with the extent of stenosis in coronary arteries. Thromb Res, 123:503–510.
43.
ParthasarathyS., BarnettJ., FongL.G.1990. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta, 1044:275–283.
44.
QiG.Q., JiaB., DuW.T., YangB.Z., XiaY., LiY.X., LiB., WeiL.Y.2006. Effects of the PON-1 activity to level of ox-LDL in patients with coronary artery disease. Lin Chuang Hui Cui, 21:1783–1784.
45.
QianS.H., QianQ.W., WangS., WangS.J.2003. Relationship between arylesterase/paraoxonase1 Q192R gene polymorphism and diabetes mellitus complicated with coronary artery disease in population of Han nationnality of zhengzhou. Zhengzhou Da Xue Xue Bao Yi Xue Ban, 38:225–227.
46.
RahmaniM., RaiszadehF., AllahverdianS., KiaiiS., NavabM., AziziF.2002. Coronary artery disease is associated with the ratio of apolipoprotein A-I/B and serum concentration of apolipoprotein B, but not with paraoxonase enzyme activity in Iranian subjects. Atherosclerosis, 162:381–389.
47.
Rodríguez-EsparragónF., Rodríguez-PérezJ.C., Hernández-TrujilloY., Macías-ReyesA., MedinaA., CaballeroA., FerrarioC.M.2005. Allelic variants of the human scavenger receptor class B type 1 and paraoxonase 1 on coronary heart disease: genotype-phenotype correlations. Arterioscler Thromb Vasc Biol, 25:854–860.
48.
RosenzweigA.2007. Scanning the genome for coronary risk. N Engl J Med, 357:497–499.
49.
RossR.1993. The pathogenesis of atherosclerosis: a perspective for the1990s. Nature, 362:801–809.
50.
RozenbergO., RosenblatM., ColemanR., ShihD.M., AviramM.2003. Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Radic Biol Med, 34:774–784.
51.
SamaniN.J., ErdmannJ., HallA.S.et al.2007. Genome-wide association analysis of coronary artery disease. N Engl J Med, 357:443–453.
52.
SarkarP.D., T MS., MadhusudhanB.2006. Association between paraoxonase activity and lipid levels in patients with premature coronary artery disease. Clin Chim Acta, 373:77–81.
SentürkT., SarandölE., GüllülüS., ErdinçS., OzdemirB., BaranI., AydinlarA.2008. Association between paraoxonase 1 activity and severity of coronary artery disease in patients with acute coronary syndromes. Acta Cardiol, 63:361–367.
55.
SharmaR., SinghB., MahajanM.2007. PON1 activity is inversely related to LDL apoB carbonyl content in patients with coronary artery disease. Kaohsiung J Med Sci, 23:225–231.
56.
ShihD.M., GuL., XiaY.R.et al.1998. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature, 394:284–287.
SinghS., VenketeshS., VermaJ.S., VermaM., LellammaC.O., GoelR.C.2007. Paraoxonase (PON1) activity in north west Indian Punjabis with coronary artery disease & type 2 diabetes mellitus. Indian J Med Res, 125:783–787.
59.
SteinbergD., ParthasarathyS., CarewT.E., KhooJ.C., WitztumJ.L.1989. Beyond cholesterol modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med, 320:915–924.
60.
StroupD.F., BerlinJ.A., MortonS.C.et al.2000. Meta-analysis of observational studies in epidemiology, a proposal for reporting. JAMA, 283:2008–2012.
SuM.X., CuiC.C., CuiH.B., WangX.Y.2006. Analysis of paraoxonase activity in the patients with coronary artery disease. Zhongguo Dong Mai Ying Hua Za Zhi, 14:521–523.
63.
SuS.Y., ChenJ.H., HuangJ.F., WangX.L., ZhaoJ.G., ShenY., QiangB.Q., GuD.F.2005. Paraoxonase gene cluster variations associated with coronary heart disease in Chinese Han women. Chin Med J (Engl), 118:1167–1174.
64.
TroughtonJ.A., WoodsideJ.V., YarnellJ.W.et al.2008. Paraoxonase activity and coronary heart disease risk in healthy middle-aged males: the PRIME study. Atherosclerosis, 197:556–563.
65.
TwardA., XiaY.R., WangX.P.et al.2002. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation, 106:484–490.
66.
van HimbergenT.M., van der SchouwY.T., VoorbijH.A., van TitsL.J., StalenhoefA.F., PeetersP.H., RoestM.2008. Paraoxonase (PON1) and the risk for coronary heart disease and myocardial infarction in a general population of Dutch women. Atherosclerosis, 199:408–414.
67.
WangM., LangX., ZouL., HuangS., XuZ.2011. Four genetic polymorphisms of paraoxonase gene and risk of coronary heart disease: a meta-analysis based on 88 case-control studies. Atherosclerosis, 214:377–385.
68.
WangX., FanZ., HuangJ.et al.2003. Extensive association analysis between polymorphisms of PON gene cluster with coronary heart disease in Chinese Han population. Arterioscler Thromb Vasc Biol, 23:328–334.
69.
WatsonA.D., BerlinerJ.A., HamaS.Y., La DuB.N., FaullK.F., FogelmanA.M., NavabM.1995. Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidised low-density lipoprotein. J Clin Invest, 96:2882–2891.
70.
YangY.H., XiaY., CuiD.S., YuanS.H., GengY.L., QiG.Q., LiuG., LiuK.S.2007. Activity of paraoxonase-1 with coronary artery disease and severity of coronary artery lesions. Lin Chuang Hui Cui, 22:1761–1764.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
